Surgically treated acromegaly patients have a similar quality of life whether controlled by surgery or requiring additional medical therapy (QuaLAT Study).


Journal

Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578

Informations de publication

Date de publication:
Oct 2021
Historique:
accepted: 04 05 2021
pubmed: 14 5 2021
medline: 18 1 2022
entrez: 13 5 2021
Statut: ppublish

Résumé

There is no consensus on quality of life (QOL) in patients with acromegaly requiring medical treatment after surgery compared with those achieving remission by surgery alone. QuaLAT is a cross-sectional study comparing QOL in surgery-only treated acromegaly patients versus those requiring medical treatment post-surgery. Patients attending clinics were identified and divided into-Group 1: patients who had surgery only and were in biochemical remission, Group 2: all patients on medical treatment post-surgery, Group 3: patients from Group 2 with biochemical control. Participants were asked to fill three questionnaires; Acromegaly Quality of Life Questionnaire (ACROQOL), 36-Item Short Form Survey (SF36), and Fatigue Severity Scale (FSS). There were 32 patients in Group 1 and 25 in Group 2. There was no difference in QOL scores between groups 1 and 2, as measured by ACROQOL (mean difference [MD] = - 2.5, 95% CI - 16.6 to 11.6; p = 0.72), SF36v2 [Physical component score (PCS) MD = - 4.9, 95% CI - 10.9 to 1.2; p = 0.12; mental component score MD = - 3.0, 95% CI - 10.5 to 4.4; p = 0.44], or FSS (MD = - 0.004, 95% CI - 1.14 to 1.33; p = 0.1). Comparison between groups 1 and 3 however showed that PCS (and 3 subdomains) was significantly better in group 3 (MD = - 8.3, 95% CI - 14.8 to -1.8; p = 0.01). All three QOL scores were lower when compared with healthy controls. Medical treatment not only achieves a QOL comparable to surgery, it may also be associated with better QOL in physical subdomains. When compared with healthy controls, QOL remains worse in treated acromegaly patients compared to controls.

Identifiants

pubmed: 33982222
doi: 10.1007/s11102-021-01153-4
pii: 10.1007/s11102-021-01153-4
pmc: PMC8416856
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

768-777

Subventions

Organisme : Ipsen Fund
ID : Medical Education Goods and Services (MEGS) grant

Informations de copyright

© 2021. The Author(s).

Références

Endocr Relat Cancer. 2017 Oct;24(10):505-518
pubmed: 28733467
J Clin Endocrinol Metab. 2014 Nov;99(11):4003-14
pubmed: 25356809
Endocrine. 2014 Nov;47(2):564-71
pubmed: 24510628
Endocr J. 2017 Jan 30;64(1):27-38
pubmed: 27681883
Health Qual Life Outcomes. 2004 Feb 27;2:13
pubmed: 14987332
Eur J Neurol. 2021 Jan;28(1):108-116
pubmed: 32920893
Eur J Endocrinol. 2008 Mar;158(3):305-10
pubmed: 18299462
Eur J Endocrinol. 2007 Oct;157(4):411-7
pubmed: 17893254
J Clin Endocrinol Metab. 2004 Nov;89(11):5369-76
pubmed: 15531483
Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82
pubmed: 19650784
Clin Endocrinol (Oxf). 2011 Nov;75(5):678-84
pubmed: 21575026
J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51
pubmed: 25356808
J Clin Endocrinol Metab. 2021 Jan 23;106(2):577-587
pubmed: 33245343
Pituitary. 2015 Dec;18(6):876-83
pubmed: 26123761
J Clin Endocrinol Metab. 2014 Dec;99(12):4438-46
pubmed: 25210882
J Epidemiol Community Health. 1999 Jan;53(1):46-50
pubmed: 10326053
J Clin Endocrinol Metab. 2014 Apr;99(4):1282-90
pubmed: 24423301
Clin Endocrinol (Oxf). 2009 May;70(5):757-68
pubmed: 19178516
J Endocrinol Invest. 2009 Dec;32(11):924-33
pubmed: 20009494
Eur J Endocrinol. 2006 Aug;155(2):269-77
pubmed: 16868140
Eur Endocrinol. 2013 Mar;9(1):32-36
pubmed: 30349608
Eur J Endocrinol. 2011 Jun;164(6):877-84
pubmed: 21464140
BMC Public Health. 2020 Jan 28;20(1):114
pubmed: 31992264
Soc Sci Med. 1995 Nov;41(10):1403-9
pubmed: 8560308
J Clin Endocrinol Metab. 2011 Aug;96(8):2405-13
pubmed: 21632808
Acta Neurochir (Wien). 2013 Sep;155(9):1637-45; discussion 1645
pubmed: 23836354
Front Endocrinol (Lausanne). 2017 Mar 03;8:40
pubmed: 28316591
Pituitary. 2014 Dec;17(6):495-9
pubmed: 24178448
BMC Endocr Disord. 2016 Apr 02;16:16
pubmed: 27039081
Eur J Endocrinol. 2020 May;182(5):R67-R82
pubmed: 32069216
BMJ Open. 2015 Jun 10;5(6):e006898
pubmed: 26063564
Can J Neurol Sci. 2014 Nov;41(6):735-41
pubmed: 25431207
Clin Endocrinol (Oxf). 2002 Aug;57(2):251-8
pubmed: 12153605
N Engl J Med. 2006 Dec 14;355(24):2558-73
pubmed: 17167139
J Clin Endocrinol Metab. 2020 Sep 1;105(9):
pubmed: 32593172

Auteurs

Muhammad Fahad Arshad (MF)

Department of Endocrinology and Diabetes, Sheffield Teaching Hospitals, Glossop Road, Sheffield, S10 2 JF, UK. m.arshad@sheffield.ac.uk.
Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK. m.arshad@sheffield.ac.uk.

Oluwafunto Ogunleye (O)

Department of Endocrinology and Diabetes, Sheffield Teaching Hospitals, Glossop Road, Sheffield, S10 2 JF, UK.

Richard Ross (R)

Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.

Miguel Debono (M)

Department of Endocrinology and Diabetes, Sheffield Teaching Hospitals, Glossop Road, Sheffield, S10 2 JF, UK.
Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH